PFE's new drug launches and Seagen acquisition are driving revenue gains despite COVID declines and market headwinds.

Pfizer’s CEO Albert Bourla disclosed that the company recently met with the Trump administration to discuss lowering U.S.

Four blue-chip stocks are trading near their 52-week lows and offering investors incredible entry points and huge dividends.

PFE lags the market as COVID sales drop and patent losses loom, but new drugs and cost cuts may fuel a comeback.

Children’s mental health has recently dominated U.S. headlines. Some commentators have blamed psychiatric medications, ...

Jefferies reaffirms its Buy rating on Pfizer and sticks to a $33 target, calling the stock undervalued at $23.35. Their ...

Three supercharged dividend stocks have the tools and intangibles to fatten investors' pocketbooks in June, and well beyond.

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of ...

The three-treatment combination included a standard chemotherapy drug, an antibody drug called cetuximab and a pill from Pfizer called Braftovi, which targets a cancer mutation called BRAF V600E.

GC Biopharma partners with Pfizer Korea to distribute Paxlovid for COVID-19 GC Biopharma announced on the 2nd that it has signed a joint sales and distribution agreement for the oral COVID-19 ...

Higher uptake of nirmatrelvir-ritonavir (Paxlovid ®) was not found to reduce COVID-19-related hospitalization or mortality risk among highly vaccinated older adults, according to findings of a ...

Last month, an average of about 350 people died each week from COVID, according to data from the CDC. With available vaccines ...